Lack of α2C-Adrenoceptor Results in Contrasting Phenotypes of Long Bones and Vertebra and Prevents the Thyrotoxicosis-Induced Osteopenia

A series of studies have demonstrated that activation of the sympathetic nervous system (SNS) causes osteopenia via β2-adrenoceptor (β2-AR) signaling. However, in a recent study, we found an unexpected and generalized phenotype of high bone mass in female mice with chronic sympathetic hyperactivity, due to double gene inactivation of adrenoceptors that negatively regulate norepinephrine release, α2A-and α2C-AR (α2A/2C-AR-/-). These findings suggest that β2-AR is not the single adrenoceptor involved in bone turnover regulation and show that α2-AR signaling may also mediate the SNS actions in the skeleton. In addition, we found that α2A/2C-AR-/- animals are resistant to the thyrotoxicosis-induced osteopenia, suggesting that thyroid hormone (TH), when in supraphysiological levels, interacts with the SNS to control bone mass and structure, and that this interaction may also involve α2-AR signaling. In the present study, to further investigate these hypotheses and to discriminate the roles of α2-AR subtypes, we have evaluated the bone phenotype of mice with the single gene inactivation of α2C-AR subtype, which mRNA expression was previously shown to be down regulated by triiodothyronine (T3). A cohort of 30 day-old female α2CAR-/- mice and their wild-type (WT) controls were treated with a supraphysiological dose of T3 for 30 or 90 days, which induced a thyrotoxic state in both mouse lineages. The micro-computed tomographic (μCT) analysis showed that α2C-AR-/- mice present lower trabecular bone volume (BV/TV) and number (Tb.N), and increased trabecular separation (Tb.Sp) in the femur compared with WT mice; which was accompanied by decreased bone strength (determined by the three-point bending test) in the femur and tibia. The opposite was observed in the vertebra, where α2C-AR-/- mice show increased BV/TV, Tb.N and trabecular thickness (Tb.Th), and decreased Tb.Sp, compared with WT animals. In spite of the contrasting bone phenotypes of the femur and L5, thyrotoxicosis negatively regulated most of the micro architectural features of the trabecular bone in both skeletal sites of WT, but not of α2C-AR-/- mice. T3 treatment also decreased biomechanical properties (maximum load and ultimate load) in the femur and tibia of WT, but not of knockout mice. The mRNA expression of osteocalcin, a marker of mature osteoblasts, and tartrate-resistant acid phosphatase, which is expressed by osteoclasts and is involved in collagen degradation, was increased by T3 treatment only in WT, and not in α2C-AR-/- mice. Altogether, these findings suggest that α2C-AR subtype mediates the effects of the SNS in the bone in a skeletal site-dependent manner, and that thyrotoxicosis depends on α2C-AR signaling to promote bone loss, which sustains the hypothesis of a TH-SNS interaction to modulate bone remodeling and structure.

[1]  David Mendelowitz,et al.  Clonidine, an α2-receptor agonist, diminishes GABAergic neurotransmission to cardiac vagal neurons in the nucleus ambiguus , 2010, Brain Research.

[2]  J. Coindre,et al.  Bone loss in hypothyroidism with hormone replacement. A histomorphometric study. , 1986, Archives of internal medicine.

[3]  C. Benhamou,et al.  Combined Effects of Exercise and Propranolol on Bone Tissue in Ovariectomized Rats , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  L. Mosekilde,et al.  Morphometric and Dynamic Studies of Bone Changes in Hypothyroidism , 1978, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[5]  A. Bianco,et al.  Effects of Thyroid Hormone Administration and Estrogen Deficiency on Bone Mass of Female Rats , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  A. Boyde,et al.  Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. , 2007, Molecular endocrinology.

[7]  J. Flier,et al.  Leptin accelerates the onset of puberty in normal female mice. , 1997, The Journal of clinical investigation.

[8]  F. Melsen,et al.  Trabecular bone remodeling and bone balance in hyperthyroidism. , 1985, Bone.

[9]  J. Marc,et al.  ADRA2A is involved in neuro-endocrine regulation of bone resorption , 2015, Journal of cellular and molecular medicine.

[10]  N. Kanbur,et al.  Osteocalcin. A biochemical marker of bone turnover during puberty , 2002, International journal of adolescent medicine and health.

[11]  H. Samuels,et al.  Depletion of L-3,5,3'-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. , 1979, Endocrinology.

[12]  L. Mosekilde,et al.  Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. , 1977, Acta endocrinologica.

[13]  N. Bonnet,et al.  Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis. , 2008, Journal of musculoskeletal & neuronal interactions.

[14]  F. Melsen,et al.  Morphometric and dynamic studies of bone changes in hyperthyroidism. , 1977, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[15]  J. Kragstrup,et al.  Effects of thyroid hormone(s) on mean wall thickness of trabecular bone packets. , 1981, Metabolic bone disease & related research.

[16]  K. Fox,et al.  Bilateral asymmetry in bone weight at various skeletal sites of the rat , 1995, The Anatomical record.

[17]  T. Scanlan,et al.  The Thyroid Hormone Receptor (TR) β-Selective Agonist GC-1 Inhibits Proliferation But Induces Differentiation and TR β mRNA Expression in Mouse and Rat Osteoblast-Like Cells , 2009, Calcified Tissue International.

[18]  Julio C. B. Ferreira,et al.  M-protein is down-regulated in cardiac hypertrophy driven by thyroid hormone in rats. , 2013, Molecular endocrinology.

[19]  Masaki Noda,et al.  Unloading Induces Osteoblastic Cell Suppression and Osteoclastic Cell Activation to Lead to Bone Loss via Sympathetic Nervous System* , 2005, Journal of Biological Chemistry.

[20]  L. Braverman,et al.  Differential responses of femoral and vertebral bones to long-term excessive L-thyroxine administration in adult rats. , 1996, European journal of endocrinology.

[21]  D. Casarini,et al.  Thyroid hormone interacts with the sympathetic nervous system to modulate bone mass and structure in young adult mice. , 2014, American journal of physiology. Endocrinology and metabolism.

[22]  Florent Elefteriou,et al.  Control of Bone Remodeling by the Peripheral Sympathetic Nervous System , 2013, Calcified Tissue International.

[23]  J. Bassett,et al.  The molecular actions of thyroid hormone in bone , 2003, Trends in Endocrinology & Metabolism.

[24]  Patricia Ducy,et al.  Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.

[25]  L. Hein,et al.  Two α2-adrenergic receptor subtypes, α2A and α2C, inhibit transmitter release in the brain of gene-targeted mice , 2002, Neuroscience.

[26]  E. Hesse,et al.  Double disruption of α2A‐ and α2C ‐adrenoceptors results in sympathetic hyperactivity and high‐bone‐mass phenotype , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  P. Delmas,et al.  Markers of bone turnover in hyperthyroidism and the effects of treatment. , 1994, The Journal of clinical endocrinology and metabolism.

[28]  S. Toh,et al.  Effect of hyperthyroidism and its treatment on bone mineral content. , 1985, Archives of internal medicine.

[29]  P. de Lange,et al.  New avenues for regulation of lipid metabolism by thyroid hormones and analogs , 2014, Front. Physiol..

[30]  Jeffrey G. Mandell,et al.  Sequence-detection system , 2018 .

[31]  C. Benhamou,et al.  Alteration of trabecular bone under chronic beta2 agonists treatment. , 2005, Medicine and science in sports and exercise.

[32]  B. Riggs,et al.  Leptin reduces ovariectomy-induced bone loss in rats. , 2001, Endocrinology.

[33]  G. Williams,et al.  Thyroid Hormone Actions in Cartilage and Bone , 2012, European Thyroid Journal.

[34]  L. Terenius,et al.  Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. , 1988, Journal of the autonomic nervous system.

[35]  O. Kozawa,et al.  AMP-activated protein kinase regulates thyroid hormone-stimulated osteocalcin synthesis in osteoblasts. , 2013, International journal of molecular medicine.

[36]  J. Marc,et al.  A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts. , 2010, Bone.

[37]  L. Hein,et al.  Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice. , 2002, Neuroscience.

[38]  J. Oppenheimer,et al.  Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. , 1991, The Journal of clinical investigation.

[39]  S. Krane,et al.  The effect of thyroid disease on calcium metabolism in man. , 1956, The Journal of clinical investigation.

[40]  M. Brede,et al.  alpha2-adrenergic receptor subtypes - novel functions uncovered in gene-targeted mouse models. , 2004, Biology of the cell.

[41]  C. Cowell,et al.  DXA for bone density measurement in small rats weighing 150-250 grams. , 1994, Bone.

[42]  Masaki Noda,et al.  Leptin regulation of bone resorption by the sympathetic nervous system and CART , 2005, Nature.

[43]  F. Gribble Alpha2A-adrenergic receptors and type 2 diabetes. , 2010, The New England journal of medicine.

[44]  F. Singer,et al.  Treatment of thyrotoxic hypercalcemia with propranolol. , 1976, New England Journal of Medicine.

[45]  C. Nelson,et al.  Correlating RANK Ligand/RANK Binding Kinetics With Osteoclast Formation and Function , 2015, Journal of cellular biochemistry.

[46]  J. Bassett,et al.  Thyroid hormone metabolism in skeletal development and adult bone maintenance , 2012, Trends in Endocrinology & Metabolism.

[47]  M. Philipp,et al.  Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. , 2004, Pharmacology & therapeutics.

[48]  R. Taylor-Gjevre,et al.  Metabolic and Clinical Consequences of Hyperthyroidism on Bone Density , 2013, International journal of endocrinology.

[49]  K. Starke,et al.  α2‐Adrenoceptors modulating neuronal serotonin release: a study in α2‐adrenoceptor subtype‐deficient mice , 2001 .

[50]  G. Williams Role of thyroid hormone receptor-α1 in endochondral ossification. , 2014, Endocrinology.

[51]  L. Hein Adrenoceptors and signal transduction in neurons , 2006, Cell and Tissue Research.

[52]  S. Neubauer,et al.  Feedback Inhibition of Catecholamine Release by Two Different &agr;2-Adrenoceptor Subtypes Prevents Progression of Heart Failure , 2002, Circulation.

[53]  Jack C. Yu,et al.  Effects of Thyroxine Exposure on Osteogenesis in Mouse Calvarial Pre-Osteoblasts , 2013, PloS one.

[54]  A. Hayman Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy , 2008, Autoimmunity.